Additional Information

Description

Benlysta (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy. By inhibiting BLyS, a cytokine essential for the survival of B cells, Benlysta reduces autoantibody production and modulates the immune response.

The injection is supplied as a sterile, preservative-free, lyophilized powder in a single-dose glass vial with a rubber stopper and a flip-off seal. Each 20 mL vial contains 400 mg of belimumab, which must be reconstituted with sterile water for injection and further diluted in 0.9% sodium chloride before intravenous administration. 

Benlysta is administered via intravenous infusion over one hour. The recommended dosing regimen for SLE consists of 10 mg/kg at weeks 0, 2, and 4, followed by maintenance doses every four weeks. For lupus nephritis, it is given at the same frequency but can be combined with corticosteroids and other immunosuppressive agents.